Tolerability of the COX-1/COX-2 inhibitor lornoxicam in the treatment of acute and rheumatic pain-Reference-Cited by-同舟云学术

Tolerability of the COX-1/COX-2 inhibitor lornoxicam in the treatment of acute and rheumatic pain

Published:2016-10 Issue:5 Volume:6 Page:445-454
ISSN:1758-1869
Container-title:Pain Management
language:en
Short-container-title:Pain Management

Author:

Parada Luis¹,Marstein Jens Pauli²,Danilov Andrey³

Affiliation:

1. Central University of Venezuela, Caracas, Venezuela

2. Takeda Pharmaceuticals International GmbH, Zurich, Switzerland

3. IM Sechenov First Moscow State Medical University, Moscow, Russia

Abstract

Aim: To assess the safety of lornoxicam with particular focus on gastrointestinal (GI) events. Methods: Data on adverse drug reactions (ADRs) were pooled from 60 comparative studies of lornoxicam. Results: A total of 6420 patients received lornoxicam, 1192 received placebo and 3770 received a comparator analgesic. ADRs were reported by 21% of lornoxicam-treated patients, with GI events the most frequent (14 vs 8% with placebo). Across 15 studies that compared lornoxicam (n = 1287) with another NSAID (n = 1010), there was a reduced risk of a GI ADR with lornoxicam (0.78 [95% CI: 0.64–0.96]; p = 0.017). Conclusion: Lornoxicam was well tolerated with the type of GI events observed consistent with the known safety profile of NSAIDs.

Publisher

Future Medicine Ltd

Subject

General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pmt.16.7

Reference36 articles.

1. Gastrointestinal Safety of Cyclooxygenase-2 Inhibitors: A Cochrane Collaboration Systematic Review

2. Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials

3. Cardiovascular Risk and Inhibition of Cyclooxygenase

4. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials

5. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Calcium complexes of oxicams: new dimensions in rheumatoid arthritis treatment;Future Medicinal Chemistry;2022-12

2. Lornoxicam in the treatment of acute and chronic musculoskeletal pain;Modern Rheumatology Journal;2022-08-23

3. Lornoxicam-Loaded Chitosan-Decorated Nanoemulsion: Preparation and In Vitro Evaluation for Enhanced Transdermal Delivery;Polymers;2022-05-09

4. Possibilities of individual choice of NSAIDs on the example of the oxicam class, taking into account clinical and pharmacological characteristics;Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova;2022

5. Presumptive Lornoxicam Intoxication in Four Dogs;Topics in Companion Animal Medicine;2021-03